INFLECTRA (infliximab-dyyb)

What Switching to INFLECTRA Means
INFLECTRA treats the same conditions Remicade does
If your doctor elects to prescribe INFLECTRA to take the place of Remicade, know that INFLECTRA was approved as a biosimilar to Remicade through a strict FDA review process.


Switching to INFLECTRA means you’re receiving the first FDA-approved biosimilar for Remicade that is indicated for the same conditions, at the same dosage strength.


If you and your doctor decide to switch to INFLECTRA, you can expect the same treatment experience you had with Remicade.

INFLECTRA is the first biosimilar to Remicade®

In studies, INFLECTRA showed no clinically meaningful differences from Remicade®
This means that INFLECTRA has passed the FDA-approval process to show that it has no clinically meaningful differences in terms of safety or effectiveness from Remicade.


Over the course of 3 separate clinical studies, INFLECTRA showed similarity to Remicade for the following conditions:

  • Rheumatoid arthritis (RA)

  • Ankylosing spondylitis (AS)

  • Crohn’s disease (CD)*


*This study was not used in the FDA-approval process.


8080 Ravines Edge Court Columbus, Ohio 43235